Antibodies

03 Apr 2019 Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting
03 Apr 2019 Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody
03 Apr 2019 Rgenix Presents Pre-Clinical Data on RGX-019 at the 2019 AACR Annual Meeting
03 Apr 2019 Alligator Bioscience: New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects
03 Apr 2019 Pieris Pharmaceuticals Presents Preclinical Data for GPC3/4-1BB Bispecific PRS-342 at the 2019 American Association for Cancer Research
02 Apr 2019 Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019
02 Apr 2019 Apexigen Presents Clinical Data On CD40 Antibody APX005M In Metastatic Melanoma At The AACR Annual Meeting 2019
02 Apr 2019 Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11
02 Apr 2019 Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019
02 Apr 2019 Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting
02 Apr 2019 Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010
02 Apr 2019 Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma
02 Apr 2019 Humanigen Announces Preliminary Results From Ifabotuzumab Phase I Study Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
02 Apr 2019 Celldex Presents Promising Data from CDX-527 Bispecific and TAM Receptor Programs at American Association for Cancer Research (AACR) Annual Meeting 2019
02 Apr 2019 FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin
01 Apr 2019 Apexigen Announces New Clinical Data on APX005M in Combination Therapy for Pancreatic Cancer at the AACR Annual Meeting 2019
01 Apr 2019 Bolt Biotherapeutics Presents Preclinical Proof of Concept Data at American Association for Cancer Research (AACR) Conference
01 Apr 2019 Merck’s KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy
01 Apr 2019 European Medicines Agency Accepts Takeda’s Marketing Authorization Application for a Subcutaneous Formulation of Vedolizumab for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis and Crohn’s Disease
01 Apr 2019 Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults
30 Mar 2019 CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis
30 Mar 2019 Northern Biologics Reports Initial Phase I Data for MSC-1 at AACR
30 Mar 2019 Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing
28 Mar 2019 Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
27 Mar 2019 Tizona Announces Initiation of Phase 1/1b Study with Novel Cancer Immunotherapy TTX-030 and First Public Presentation of Pre-Clinical Data with TTX-030 at AACR 2019

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top